Vertex Pharmaceuticals (VRTX) Free Cash Flow (2009 - 2026)
Vertex Pharmaceuticals (VRTX) posted quarterly Free Cash Flow of $1.3 billion for Q1 2026, up 66.37% year-over-year from $778.2 million in Q1 2025, and up 271.4% quarter-over-quarter from $348.6 million in Q4 2025.
Vertex Pharmaceuticals (VRTX) Free Cash Flow (2009 - 2026) Analysis & Trends
Vertex Pharmaceuticals' Free Cash Flow history runs 18 years deep, the most recent figure standing at $1.3 billion for Q1 2026.
- In Q1 2026, Free Cash Flow rose 66.37% year-over-year to $1.3 billion; the TTM figure through Mar 2026 stood at $3.7 billion (up 396.75% YoY), while the FY2025 annual figure was $3.2 billion, up 504.13% from the prior year.
- Free Cash Flow for Q1 2026 stood at $1.3 billion, up from $348.6 million in the prior quarter.
- The five-year high for Free Cash Flow was $1.3 billion in Q3 2024, with the low at -$3.8 billion in Q2 2024.
- The 5-year median for Free Cash Flow is $927.4 million (2025), against an average of $644.7 million.
- The sharpest annual moves came in 2022 and 2024: Free Cash Flow soared 535.3% in 2022, then tumbled 455.66% in 2024.
- Vertex Pharmaceuticals' Free Cash Flow stood at $1.0 billion in 2022, then plunged by 83.11% to $176.5 million in 2023, then jumped by 178.75% to $492.0 million in 2024, then declined by 29.15% to $348.6 million in 2025, then surged by 271.4% to $1.3 billion in 2026.
- Business Quant data shows VRTX's Free Cash Flow at $1.3 billion in Q1 2026, $348.6 million in Q4 2025, and $1.1 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -389.61 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 437.80 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 477.44 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 292.04 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -95.09 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | -268.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.01 Bn |
| Jun 30, 2026 | 1.01 Bn |
| Mar 31, 2026 | 1.29 Bn |
| Mar 31, 2026 | 1.29 Bn |
| Dec 31, 2025 | 348.60 Mn |
| Dec 31, 2025 | 348.60 Mn |
| Sep 30, 2025 | 1.14 Bn |
| Sep 30, 2025 | 1.14 Bn |
| Jun 30, 2025 | 927.40 Mn |
| Jun 30, 2025 | 927.40 Mn |
| Mar 31, 2025 | 778.20 Mn |
| Mar 31, 2025 | 778.20 Mn |
| Dec 31, 2024 | 492.00 Mn |
| Dec 31, 2024 | 492.00 Mn |
| Sep 30, 2024 | 1.30 Bn |
| Sep 30, 2024 | 1.30 Bn |
| Jun 30, 2024 | -3.82 Bn |
| Jun 30, 2024 | -3.82 Bn |
| Mar 31, 2024 | 1.24 Bn |
| Mar 31, 2024 | 1.24 Bn |